Clinical Trial Update: A Study of the Safety and Efficacy of Tarceva in Patients With First Relapse of Grade IV Glioma (Glioblastoma Multiforme) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Tarceva (erlotinib) for safety and efficacy in patients with first relapse glioblastoma; the trial has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Genentech, Inc. | Conditions: Glioblastoma | Phase 2 | Status: COMPLETED